Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adult ADHD Clear all
Completed No phase listed Observational Accepts healthy volunteers

Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)

NCT00181857
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Not applicable Interventional

Assessing Mobile Apps for Adult ADHD

NCT06256003
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
UC-A, UC-N
Device
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 16, 2026, 9:14 PM EDT
Not listed No phase listed Observational

Screening Protocol for Adults With ADHD

NCT00592254
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Sulfate, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

NCT00553319
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder, Cocaine Dependence
Interventions
Placebo, Adderall-XR
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 16, 2026, 9:14 PM EDT
Recruiting Not applicable Interventional

Binaural Beats Stimulation for Adults With Attention-Deficit/Hyperactivity Disorder

NCT07793045
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Music-Based Binaural Beats Stimulation, Music Listening Without Binaural Beats
Behavioral
Lead sponsor
California State University, San Bernardino
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 16, 2026, 9:14 PM EDT
Completed No phase listed Observational

Safety Study of Atomoxetine and Cerebrovascular Outcomes

NCT00634439
View directory record Official record
Conditions
Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions
atomoxetine, Stimulants, No intervention (general population)
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
72,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Sep 16, 2026, 9:14 PM EDT
Completed No phase listed Observational

Autism Spectrum Disorders (ASD) Driving Study

NCT01263756
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00683462
View directory record Official record
Conditions
ADHD
Interventions
Placebo, AZD3480
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 29, 2009 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT02604407
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 4 Interventional

Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder

NCT00181987
View directory record Official record
Conditions
ADHD, Bipolar Disorder
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients

NCT00664703
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Lobeline sulfate, Methylphenidate HCl, Placebo
Drug
Lead sponsor
Yaupon Therapeutics
Industry
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NCT04839562
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Solriamfetol 75 MG, Solriamfetol 150 MG, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00880217
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

NCT03605680
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional

PRC-063 in an ADULT Workplace Environment

NCT02225639
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
PRC-063 25 mg, Placebo, PRC-063 35 mg, PRC-063 45 mg, PRC-063 55 mg, PRC-063 70 mg, PRC-063 85 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Newport Beach, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03618030
View directory record Official record
Conditions
ADHD
Interventions
PRC-063 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Purdue Pharma, Canada
Industry
Eligibility
18 Years to 60 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NCT05683249
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT03834766
View directory record Official record
Conditions
ADHD
Interventions
AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 16, 2026, 9:14 PM EDT
Withdrawn Phase 3 Interventional

A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

NCT00458445
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPD465, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 4 Interventional Results available

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

NCT02096952
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Interventions
Methylphenidate extended-release liquid formulation
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

NCT03605836
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine SR, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 4 Interventional

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

NCT00190879
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Interventions
Atomoxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Wildomar, California • Bradenton, Florida • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2007 · Synced Sep 16, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

NCT01012375
View directory record Official record
Conditions
Adult ADHD
Interventions
AZD1446, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Los Alamitos, California • Fort Myers, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 16, 2026, 9:14 PM EDT